Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Left Atrial Appendages Occlusion: Current Status and Prospective

  • Received : 2018.07.11
  • Accepted : 2018.07.17
  • Published : 2018.08.30
⟨ Previous Next ⟩

Abstract

Stroke continues to be a major cause of morbidity and mortality in atrial fibrillation (AF) patients. Oral anticoagulation (OAC) provides protection against stroke and peripheral embolization in AF but significant proportion of patients could not be started on anticoagulation because of bleeding complications. Left atrial appendage harbors clot in about 90% of nonvalvular AF. The advent of left atrial appendage occlusion (LAAO) techniques has provided these patients with alternative to OAC for stroke prophylaxis. Multiple LAAO devices are currently available with Watchman and Amulet being the most commonly used in clinical practice. Randomized studies are available for Watchman device only. Data on Amplatzer Cardiac Plug, Amulet and Lariat devices are limited by the paucity of randomized data. Long-term data on different LAAO techniques are showing promising results. Device related thrombosis continues to be a serious complication associated with LAAO. Future studies should look into comparative effectiveness between different LAAO techniques, optimal patient selection, risk of complications, and anticoagulant treatment after LAAO. This article aims to provide current available evidence on efficacy and safety of different LAAO devices and future prospective.

Keywords

References

  1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5. https://doi.org/10.1001/jama.285.18.2370
  2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. https://doi.org/10.1161/CIRCULATIONAHA.105.595140
  3. Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008;31:55-62. https://doi.org/10.1002/clc.20138
  4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007
  5. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. https://doi.org/10.1016/S0140-6736(07)61233-1
  6. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-9. https://doi.org/10.1016/0003-4975(95)00887-X
  7. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20. https://doi.org/10.1056/NEJM200105103441901
  8. Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke 2007;38:624-30. https://doi.org/10.1161/01.STR.0000250166.06949.95
  9. U.S. Food and Drug Administration. Watchman LAA closure technology -P130013 [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2015 [cited 2018 May 17]. Available form: https://www.accessdata.fda.gov/cdrh_docs/pdf13/p130013a.pdf.
  10. Holmes DR, Reddy VY, Turi ZG, et al.PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42. https://doi.org/10.1016/S0140-6736(09)61343-X
  11. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1-12. https://doi.org/10.1016/j.jacc.2014.04.029
  12. Reddy VY, Gibson DN, Kar S, et al. Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2017;69:253-61.
  13. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417-24. https://doi.org/10.1161/CIRCULATIONAHA.110.976449
  14. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015;65:2614-23. https://doi.org/10.1016/j.jacc.2015.04.025
  15. Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465-74. https://doi.org/10.1093/eurheartj/ehv730
  16. Betts TR, Leo M, Panikker S, et al. Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: a multicenter registry. Catheter Cardiovasc Interv 2017;89:484-92. https://doi.org/10.1002/ccd.26782
  17. Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. J Am Coll Cardiol 2013;61:1790-8. https://doi.org/10.1016/j.jacc.2013.01.061
  18. Reddy VY, Akehurst RL, Armstrong SO, et al. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace 2016;18:979-86. https://doi.org/10.1093/europace/euv412
  19. Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Beard SM, Holmes DR Jr. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J Am Coll Cardiol 2015;66:2728-39. https://doi.org/10.1016/j.jacc.2015.09.084
  20. Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 2016;11:1170-9. https://doi.org/10.4244/EIJY15M01_06
  21. Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention 2016;11:1188-94. https://doi.org/10.4244/EIJY14M10_12
  22. Landmesser U, Schmidt B, Nielsen-Kudsk JE, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention 2017;13:867-76. https://doi.org/10.4244/EIJ-D-17-00493
  23. Urena M, Rodes-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 2013;62:96-102. https://doi.org/10.1016/j.jacc.2013.02.089
  24. Berti S, Pastormerlo LE, Rezzaghi M, et al. Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation. Heart 2016;102:1969-73. https://doi.org/10.1136/heartjnl-2015-309150
  25. Koskinas KC, Shakir S, Fankhauser M, et al. Predictors of early (1-week) outcomes following left atrial appendage closure with Amplatzer devices. JACC Cardiovasc Interv 2016;9:1374-83. https://doi.org/10.1016/j.jcin.2016.04.019
  26. Kleinecke C, Park JW, Godde M, Zintl K, Schnupp S, Brachmann J. Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet. Cardiol J 2017;24:131-8. https://doi.org/10.5603/CJ.a2017.0017
  27. Lopez Minguez JR, Asensio JM, Gragera JE, et al. Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. Heart 2015;101:877-83. https://doi.org/10.1136/heartjnl-2014-306332
  28. Gloekler S, Shakir S, Doblies J, et al. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Clin Res Cardiol 2015;104:656-65. https://doi.org/10.1007/s00392-015-0828-1
  29. Abualsaud A, Freixa X, Tzikas A, et al. Side-by-side comparison of LAA occlusion performance with the Amplatzer cardiac plug and Amplatzer Amulet. J Invasive Cardiol 2016.28:34-8.
  30. Genovesi S, Slaviero G, Porcu L, et al. Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: peri-procedural outcomes from an Italian dialysis population. Int J Cardiol 2018;262:38-42. https://doi.org/10.1016/j.ijcard.2018.03.083
  31. Lee OH, Kim JS, Pak HN, et al. Feasibility of left atrial appendage occlusion for left atrial appendage thrombus in patients with persistent atrial fibrillation. Am J Cardiol 2018;121:1534-9. https://doi.org/10.1016/j.amjcard.2018.02.045
  32. Lakkireddy D, Afzal MR, Lee RJ, et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm 2016;13:1030-6. https://doi.org/10.1016/j.hrthm.2016.01.022
  33. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2013;62:108-18. https://doi.org/10.1016/j.jacc.2012.06.046
  34. Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 2014;64:565-72. https://doi.org/10.1016/j.jacc.2014.03.057
  35. Ailawadi G, Gerdisch MW, Harvey RL, et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial. J Thorac Cardiovasc Surg 2011;142:1002-9, 1009.e1. https://doi.org/10.1016/j.jtcvs.2011.07.052
  36. Regueiro A, Bernier M, O'Hara G, et al. Left atrial appendage closure: initial experience with the ultraseal device. Catheter Cardiovasc Interv 2017;90:817-23. https://doi.org/10.1002/ccd.26870
  37. Coherex WAVECREST I left atrial appendage occlusion study [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2015 [cited 2018 May 15]. Available form: https://clinicaltrials.gov/ct2/show/NCT02239887?cond=WAVECREST&rank=1.
  38. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg 2015;47:847-54. https://doi.org/10.1093/ejcts/ezu291
  39. Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol 2018;71:1528-36. https://doi.org/10.1016/j.jacc.2018.01.076
  40. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007;49:1490-5. https://doi.org/10.1016/j.jacc.2007.02.035
  41. Main ML, Fan D, Reddy VY, et al. Assessment of device-related thrombus and associated clinical outcomes with the Watchman left atrial appendage closure device for embolic protection in patients with atrial fibrillation (from the PROTECT-AF trial). Am J Cardiol 2016;117:1127-34. https://doi.org/10.1016/j.amjcard.2016.01.039
  42. Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology). J Am Coll Cardiol 2013;61:2551-6. https://doi.org/10.1016/j.jacc.2013.03.035
  43. Meincke F, Schmidt-Salzmann M, Kreidel F, Kuck KH, Bergmann MW. New technical and anticoagulation aspects for left atrial appendage closure using the WATCHMAN(R) device in patients not taking warfarin. EuroIntervention 2013;9:463-8. https://doi.org/10.4244/EIJV9I4A75
  44. Bosche LI, Afshari F, Schone D, Ewers A, Mugge A, Gotzmann M. Initial experience with novel oral anticoagulants during the first 45 days after left atrial appendage closure with the Watchman device. Clin Cardiol 2015;38:720-4. https://doi.org/10.1002/clc.22478
  45. Enomoto Y, Gadiyaram VK, Gianni C, et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm 2017;14:19-24. https://doi.org/10.1016/j.hrthm.2016.10.020
  46. Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017;70:2964-75. https://doi.org/10.1016/j.jacc.2017.10.021
  47. Lopez-Minguez JR, Nogales-Asensio JM, Infante De Oliveira E, et al. Long-term event reduction after left atrial appendage closure. Results of the Iberian Registry II. Rev Esp Cardiol (Engl Ed) 2018:S1885-5857(18)30112-9.
  48. Nietlispach F, Gloekler S, Krause R, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv 2013;82:283-9. https://doi.org/10.1002/ccd.24872
  49. Regueiro A, Cruz-Gonzalez I, Bethencourt A, et al. Long-term outcomes following percutaneous left atrial appendage closure in patients with atrial fibrillation and contraindications to anticoagulation. J Interv Card Electrophysiol 2018;52:53-9. https://doi.org/10.1007/s10840-018-0356-9
  50. Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm 2015;12:1501-7. https://doi.org/10.1016/j.hrthm.2015.03.020
  51. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104. https://doi.org/10.1161/CIR.0000000000000040
  52. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609-78. https://doi.org/10.1093/europace/euw295
  53. Cruz-Gonzalez I, Palazuelos Molinero J, Valenzuela M, et al. Brain natriuretic peptide levels variation after left atrial appendage occlusion. Catheter Cardiovasc Interv 2016;87:E39-43. https://doi.org/10.1002/ccd.25985
  54. Majunke N, Sandri M, Adams V, et al. Atrial and brain natriuretic peptide secretion after percutaneous closure of the left atrial appendage with the Watchman device. J Invasive Cardiol 2015.27:448-52.
  55. Lakkireddy D, Turagam M, Afzal MR, et al. Left atrial appendage closure and systemic homeostasis: the LAA HOMEOSTASIS study. J Am Coll Cardiol 2018;71:135-44. https://doi.org/10.1016/j.jacc.2017.10.092
  56. Afzal MR, Kanmanthareddy A, Earnest M, et al. Impact of left atrial appendage exclusion using an epicardial ligation system (LARIAT) on atrial fibrillation burden in patients with cardiac implantable electronic devices. Heart Rhythm 2015;12:52-9. https://doi.org/10.1016/j.hrthm.2014.09.053
  57. Badhwar N, Lakkireddy D, Kawamura M, et al. Sequential percutaneous LAA ligation and pulmonary vein isolation in patients with persistent AF: initial results of a feasibility study. J Cardiovasc Electrophysiol 2015;26:608-14. https://doi.org/10.1111/jce.12655
  58. Starck CT, Steffel J, Emmert MY, et al. Epicardial left atrial appendage clip occlusion also provides the electrical isolation of the left atrial appendage. Interact Cardiovasc Thorac Surg 2012;15:416-8. https://doi.org/10.1093/icvts/ivs136
  59. aMAZE Study: LAA ligation adjunctive to PVI for persistent or longstanding persistent atrial fibrillation (aMAZE) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2018 [cited 2018 May 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02513797.
  60. AMPLATZERTM AmuletTM LAA Occluder trial (Amulet IDE) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2018 [cited 2018 May 17]. Available form: https://clinicaltrials.gov/ct2/show/NCT02879448?cond=Amplatzer&draw=2&rank=1.
  61. Left atrial appendage closure vs. novel anticoagulation agents in atrial fibrillation (PRAGUE-17) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2016 [cited 2018 May 17]. Available form: https://clinicaltrials.gov/ct2/show/NCT02426944?cond=PRAGUE+17&rank=1.
  62. Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2018 [cited 2018 May 17]. Available form: https://clinicaltrials.gov/ct2/show/NCT02928497?cond=ASAP+TOO&rank=1.

Cited by

  1. Outcomes of left atrial appendage occlusion using the AtriClip device: a systematic review vol.29, pp.5, 2019, https://doi.org/10.1093/icvts/ivz156
  2. Left Atrial Appendage Closure and Pulmonary Vein Isolation vol.47, pp.1, 2020, https://doi.org/10.14503/thij-19-7061
  3. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac vol.36, pp.4, 2018, https://doi.org/10.1002/joa3.12338
  4. Long-Term Effect of Left Atrial Appendage Occlusion in Treating Patients with Previous Ischemic Stroke on the Disease Recurrence vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/6991002
  5. Current practice and future prospects in left atrial appendage occlusion vol.44, pp.7, 2021, https://doi.org/10.1111/pace.14284
  6. Management of peri‐device leak following left atrial appendage closure: A systematic review vol.98, pp.2, 2021, https://doi.org/10.1002/ccd.29495